In this interview with Oncology Data Advisor, Ms. Rowe and Ms. Vigil Schattinger discuss their own experiences with medical aid in dying, explain their work to spread awareness and provide education to the community, and share additional advice for nurses on how to engage patients and families in meaningful conversations about this important issue.

Raising Awareness About Medical Aid in Dying With Janet Rowe and Lisa Vigil Schattinger

In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).

Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ

In honor of Gallbladder and Bile Duct Cancer Awareness Month this February, Fellows Forum members Dr. Waqas Haque and Dr. Matthew Hadfield sat down for a discussion on the challenges in diagnosis of gallbladder and bile duct cancers and the importance of genetic sequencing for making targeted treatments available for patients.

Gallbladder and Bile Duct Cancer Awareness Month: Improving Screening and Treatment Options

In this interview, Jason Mouabbi, MD, an Oncology Data Advisor Editorial Board Member and Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, sat down with Valerie Brutus, MD, FACS, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, and Elizabeth Stirling Craig, MD, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, to discuss improving breast cancer surgical outcomes with lymphovenous bypass surgery.

Dr. Mouabbi engages Dr. Brutus and Dr. Craig in a thought-provoking discussion about lymphovenous bypass surgery: what it is, who qualifies for this procedure, its viability, what to expect from this procedure and its treatment process, and more about breast cancer surgical outcomes.

Improving Breast Cancer Surgical Outcomes With Lymphovenous Bypass

In this installment of Oncology Data Advisor's Exploring Artificial Intelligence in Oncology series, Dr. Waqas Haque, Fellows Forum member and incoming Hematology/Oncology Fellow at the University of Chicago, speaks with Tracey Sikora, Co-Founder of Every Cure, a nonprofit organization whose mission is to repurpose existing FDA-approved drugs for other indications, especially in rare diseases. 

Check out the discussion to learn more about: 
•	Challenges in finding treatments for rare diseases, including sparse data, low patient numbers, and lack of financial incentive for pharmaceutical companies
•	Every Cure’s mission to unlock the potential of drugs that are already on the market
•	Harnessing the latest AI and machine learning technology to structure data in a biomedical knowledge graph, looking at drugs, diseases, pathways, and targets
•	Barriers in drug repurposing, including clinical validation and eventual approval
•	The Advanced Research Projects Agency for Health (ARPA-H) grant and the importance of federal funding for rare disease research
•	How to develop efficient clinical trials without a large sample size
•	The future of AI-enabled drug discovery in oncology 
•	And more!

Every Cure: Unlocking Drug Potential With Artificial Intelligence With Waqas Haque and Tracey Sikora

In this video, Dr. Assuntina G. Sacco, Associate Professor of Internal Medicine, Co-Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center, and Disease Team Leader–Head and Neck at UC San Diego Moores Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: New Insights and Real-World Evidence for Improved Patient Outcomes. Dr. Sacco shares insights into targeted mutations to test for, recommendations for patient education, the future of HPV therapeutic vaccines, monitoring for immune-related adverse events, and more!

Claim free CME/NCPD credit for Dr. Sacco's activity here: https://www.i3health.com/course-information/recurrent-and-metastatic-hnscc-new-insights-and-real-world-evidence-for-improved-patient-outcomes

Recurrent/Metastatic HNSCC: Answers To Frequently Asked Questions With Assuntina G. Sacco, MD

The Fellow on Call and Fellowship Research at ASCO: Ronak Mistry, DO, and Vivek Patel, MD

Listen now to this CME-accredited podcast, part of the Multiple Myeloma Task Force series, where we will explore strategies for mitigating disease burden and addressing health care disparities in patients with relapsed/refractory multiple myeloma. This session brings together expert insights from Task Force Co-Chairs, Dr. Sikander Ailawadhi, Professor of Medicine at Mayo Clinic, and Dr. Rahul Banerjee, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington. Their consensus-driven perspectives will provide valuable guidance on improving patient outcomes and equity in care for multiple myeloma.

To learn more about the task force, read the position statement or revisit the youtube live please visit: https://i3health.com/course-information/podcast-rrmm

Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma

i3 Health is pleased to invite you to Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, a free, live webinar held on November 7 at 10:00 am Eastern and November 19 at 11:30 am Eastern. This interview features an exclusive preview from the two webinar co-chairs, Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas MD Anderson Cancer Center. Click below to register for this insightful webinar and enhance your understanding of genetic testing and counseling in cancer care!

Register for the webinar: https://i3health.com/course-information/pathways-to-precision-integrating-genetic-counseling-and-testing-into-cancer-care

Exclusive Sneak Peek: Unlocking What's Next in Genetic Counseling and Cancer Care!

Join Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, in Module 1 of this podcast series as she explores the challenges of diagnosing systemic mastocytosis (SM), a rare and often under recognized mast cell disease. 

In this episode, Dr. Castells discusses the wide range of SM symptoms—including anaphylaxis, cutaneous, gastrointestinal, neuropsychiatric, and musculoskeletal manifestations—and offers essential guidance on recognizing the signs, confirming the diagnosis, and improving patient outcomes through early intervention. 

Listen now to enhance your clinical knowledge and be sure to claim your credit after the episode!

Click on the link to claim your credit now: https://bit.ly/3Y3ivHM

Click here to continue listening to Module 2 of this podcast series: https://bit.ly/43VoFNP

Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies - Module 1

In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments.

Click here to go back and listen to module 1 of this podcast series: https://bit.ly/4iYmYD2

Click here to claim your CME/NCPD credit: https://bit.ly/44yO9RB

Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes  Module 2

Read the full article here: https://oncdata.com/reimagining-oncology-nursing-through-ai  

In this episode of the Exploring AI in Oncology series, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Kathleen McGrow, Sangeeta Agarawal, and Marc Perkins-Carrillo about their presentation at the Oncology Nursing Society (ONS) Congress about the intersection of artificial intelligence (AI) and oncology nursing. Their conversation highlights the transformative potential of AI in nursing, the skills needed to navigate this evolving landscape, and the ethical considerations that must guide its implementation.

Reimagining Oncology Nursing Through AI Innovations: Waqas Haque, Kathleen McGrow, Sangeeta Agarawal, Marc Perkins-Carrillo

Read the full article for this interview here: https://oncdata.com/standard-model-biomedicine 

Artificial intelligence (AI) is rapidly transforming the landscape of oncology, offering new tools to improve patient care and accelerate research. In this episode of Exploring AI in Oncology, Dr. Waqas Haque sat down with Kevin Brown, Founder and CEO of Standard Model Biomedicine, to discuss the challenges and opportunities of implementing AI in cancer care.


Building Effective AI Foundation Models at Standard Model Biomedicine With Kevin Brown and Waqas Haque, MD, MPH

Biliary tract cancer (BTC) presents a complex puzzle for the interprofessional healthcare team. With its diverse subtypes and unique molecular features, diagnosis and treatment require a personalized approach. Stay ahead of the curve with insights from leading experts, Dr. Anjana Pillai and Dr. Rachna Shroff, as they explore the latest genomic research, targeted therapies, and emerging treatment strategies in this dynamic podcast. Listen now to hear the Multidisciplinary Task Force perspective and strategies to optimize patient care in this rapidly evolving landscape.

Click here to claim your credit for this podcast:

Challenges and Innovations in Biliary Tract Cancer: A Multidisciplinary Task Force Perspective

A Return on Humanity: How the American Cancer Society Uses AI to Improve Patient Care


Join i3 Health for a special live webinar, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, being held on Thursday, July 17th at 12:00 pm Eastern and on Tuesday, August 5th at 3:00 pm Eastern. In this exclusive event, Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, will share his expertise and latest insights in the treatment of NETs.

In this interview, Dr. Chauhan shares a preview of the topics he is excited to highlight during the webinar, including the recent advances which are transforming patient care, the emerging field of theranostics, the evolving role of multidisciplinary care, and practical tips for effective team collaboration.

Don’t miss this opportunity to learn from one of the leading voices in NETs care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!

Register Here! 

July 17, 2025 @ 12:00 PM ET: https://us02web.zoom.us/webinar/register/WN_2VJ0PmYISae4gAh2KxNlnQ#/registration

August 5, 2025 @ 3:00 PM ET: https://us02web.zoom.us/webinar/register/WN_teUE5QgyQJ6sYaLRrkNp9g#/registration

Exploring the Evolution of Neuroendocrine Tumor Diagnostics and Therapeutics: A Webinar Preview With Aman Chauhan, MD

As research in dedifferentiated liposarcoma (DDLPS) continues to advance, the importance of multidisciplinary collaboration and access to innovative therapies remains at the forefront of patient care. Recently, Dr. Richard Riedel of Duke Cancer Institute and Dr. Candace Haddox of Dana-Farber Cancer Institute co-chaired i3 Health’s DDLPS Task Force activity, which brought together a panel of experts to address the complexities of this rare and challenging sarcoma subtype. With new clinical trials underway and a growing understanding of the disease’s molecular landscape, Dr. Riedel and Dr. Haddox sat down to highlight promising research directions and insights in honor of Sarcoma Awareness Month in July.

After listening to the interview, stay tuned to hear the full accredited podcast with Dr. Riedel and Dr. Haddox, and click the link below to claim free CME/AAPA credit.

Click the links below for the Task Force activity!
- Accredited CME/AAPA Podcast: i3health.com/course-information/podcast-ddlps
- Position Statement Published in Cancer Treatment Reviews: www.cancertreatmentreviews.com/article/S…/fulltext
- Live Task Force Recording: youtu.be/Otr5_tiFQ68

Additional Insights in Dedifferentiated Liposarcoma With Richard F. Riedel, MD, and Candace L. Haddox, MD

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education. 

Click the links below for the full CME activity!

Module 1: https://bit.ly/3X8apxa
Module 2 : https://bit.ly/41rS14I
Module 3: https://bit.ly/4b9JU00


And view the slide decks here:

Module 1: https://bit.ly/4l0NTzc
Module 2: https://bit.ly/4fdXwti
Module 3: https://bit.ly/40AkmoP

Multicancer Early Detection: A Fellow’s Perspective With Waqas Haque, MD, MPH

oin i3 Health for a special live webinar, Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy, being held on Wednesday, July 30 at 5:00 pm ET. In this exclusive event, Dr. Mathew Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will share his expertise and latest insights in the treatment of hereditary ATTR-CM.

In this interview, Dr. Maurer shares a preview of the topics he is excited to highlight during the webinar, including signs and symptoms to aid in early diagnosis, advances in genetic testing and new diagnostic modalities, novel therapies that are improving outcomes, and the role of interdisciplinary collaboration.

Don’t miss this opportunity to learn from one of the leading voices in hereditary ATTR-CM care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!

Register Here: bit.ly/3UgV7nF

Unmasking Hereditary ATTR-CM: A Webinar Preview With Mathew Maurer, MD

i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC). 

In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!

Click below to complete the claim your CE credit:
Module 1: https://bit.ly/49NCaQu

Click below to complete the next Module in this series, Current and Emerging Treatments for HER2-Mutated NSCLC
Module 2: https://bit.ly/405xEJO

Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 1

i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC).

In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!

Click below to complete the claim your CE credit:
Module 2: https://bit.ly/405xEJO

Click below to complete the Module 1 from this series, HER2 in NSCLC: Actionable Insights and Testing Recommendations
Module 1: https://bit.ly/49NCaQu

Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 2

Genetic testing and counseling are crucial components of precision medicine in cancer care, enabling clinicians to deliver the right care, to the right patient, at the right time. i3 Health’s educational activity, Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, provides a comprehensive foundation for incorporating these tools into practice. In this follow-up interview to the activity, co-chairs Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor at MD Anderson Cancer Center, share advances that have occurred in the field since the activity was recorded, including clinical trial updates and novel insights for clinicians.

Click here to complete the free CME/NCPD/CE activity: bit.ly/3HqXjpX

Additional Advances in Genetic Counseling and Testing in Cancer Care With Filipa Lynce, MD, and Catherine Skefos, MA, MS, CGC

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!

Click here to claim you CE credit for this activity: https://bit.ly/45u106o

Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!

Click here to claim credit for this activity: https://bit.ly/3HtOziO

Click here to listen to Module 1 of this series: https://bit.ly/45u106o

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2

Last Chance: Multiple Myeloma Task Force Podcast

Don't miss your final opportunity to listen to this CME/NCPD-accredited podcast on Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Healthcare Disparities in Relapsed/Refractory Multiple Myeloma. Last chance to listen and claim credit is September 10, 2025.

Hear from Task Force Co-Chairs Dr. Sikander Ailawadhi (Mayo Clinic) and Dr. Rahul Banerjee (Fred Hutchinson Cancer Center/University of Washington) as they discuss strategies for improving patient outcomes and addressing healthcare disparities in relapsed/refractory multiple myeloma.

Click here to claim your CME/NCPD credit: https://bit.ly/4e25pQP

EXPIRING SOON! Mitigating Disease Burden and Healthcare Disparities in Multiple Myeloma

Click here to view the full article on Oncology Data Advisor: https://oncdata.com-ai-ascomind 

ASCOmind is a novel artificial intelligence (AI) framework designed to help clinicians, researchers, and industry teams synthesize the vast amount of data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Xiaoyan Wang, PhD, Research Professor at Tulane University, and William Oh, MD, Professor of Internal Medicine at Yale School of Medicine, about the development, integration, and benefits of this valuable tool. 

From Abstracts to Action: How ASCOmind Streamlines Oncology Insights With Xiaoyan Wang, PhD; William Oh, MD; and Waqas Haque, MD, MPH

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.

Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!

Click the link to claim your CE credit:

Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Popular tracks by Oncology Data Advisor®